NCT03427840

Brief Summary

The primary indication for superior hypogastric plexus (SHP) block is visceral pelvic pain, most commonly from malignancy of the ovary, uterus, cervix, bladder, rectum or prostate. Per-cutaneous SHP blocks should be done under guidance of ultrasonography, fluoroscopy, magnetic resonance or computed tomography. During minimally invasive laparoscopic surgery, percutaneous technique can be done under the guidance of cameras.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 9, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

March 18, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2018

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

March 20, 2018

Status Verified

March 1, 2018

Enrollment Period

3 months

First QC Date

February 1, 2018

Last Update Submit

March 17, 2018

Conditions

Keywords

Superior Hypogastric Plexus BlockHysterectomyMinimally invasive surgeryLaparoscopyPainGynecologic Disease

Outcome Measures

Primary Outcomes (5)

  • postoperative pain scores (PACU)

    Patients' pain scores will be scored with a 10 cm Visual Analogue Scale (VAS). Each will be scored between 0-10 (0: no pain; 10: worst pain ever)

    1 hour (postoperatively)

  • postoperative opioid/NSAID consumption (PACU)

    nonsteroid antiinflammatory drugs (NSAID) or opioid drugs that are applied to patients will be noted down.

    1 hour (postoperatively)

  • rescue analgesic time

    Time to first analgesic demand at gynecology ward (after transfer from PACU to gynecology ward)

    48 hours (first analgesic demand time will be noted down)

  • postoperative pain scores (ward)

    Patients' pain scores will be scored with a 10 cm Visual Analogue Scale (VAS). Each will be scored between 0-10 (0: no pain; 10: worst pain ever)

    48 hours (postoperatively)

  • postoperative opioid/NSAID consumption (ward)

    NSAID or opioid drugs that are applied to patients will be noted down. Target VAS score for NSAID is \>4; if there is no response to NSAID and pain is worsening opioid drugs will be applied

    48 hours (total)

Secondary Outcomes (3)

  • Intraoperative hemodynamics

    from SHP block to the end of the surgery (approximately 15 min)

  • length of stay

    3-5 days (expected)

  • complications due to SHP block

    3-5 days (from surgery to discharge from the hospital)

Study Arms (2)

Hypo

The participants with a superior hypogastric block

Procedure: Procedure/Surgery: superior hypogastric block

NoHypo

The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)

Interventions

superior hypogastric blockade during surgery

Hypo

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailspatients who are scheduled for hysterectomy
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients who are scheduled for elective laparoscopic hysterectomy under general anesthesia.

You may qualify if:

  • ASA I - II
  • Elective laparoscopic hysterectomy

You may not qualify if:

  • ASA III
  • Different kind of surgery
  • Known allergy to local anesthetic drugs
  • Different analgesia protocol (ie: epidural, TAP block,..)
  • Refusal of the patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Derince Training and Research Hospital

Kocaeli, Derince, 41900, Turkey (Türkiye)

RECRUITING

Related Publications (5)

  • Song T, Kim MK, Jung YW, Yun BS, Seong SJ, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Minimally invasive compared with open surgery in patients with borderline ovarian tumors. Gynecol Oncol. 2017 Jun;145(3):508-512. doi: 10.1016/j.ygyno.2017.03.019. Epub 2017 Apr 2.

  • Lovich-Sapola J, Smith CE, Brandt CP. Postoperative pain control. Surg Clin North Am. 2015 Apr;95(2):301-18. doi: 10.1016/j.suc.2014.10.002. Epub 2015 Jan 24.

  • Sindt JE, Brogan SE. Interventional Treatments of Cancer Pain. Anesthesiol Clin. 2016 Jun;34(2):317-39. doi: 10.1016/j.anclin.2016.01.004.

  • Erdine S, Yucel A, Celik M, Talu GK. Transdiscal approach for hypogastric plexus block. Reg Anesth Pain Med. 2003 Jul-Aug;28(4):304-8. doi: 10.1016/s1098-7339(03)00191-3.

  • Aytuluk HG, Kale A, Basol G. Laparoscopic Superior Hypogastric Blocks for Postoperative Pain Management in Hysterectomies: A New Technique for Superior Hypogastric Blocks. J Minim Invasive Gynecol. 2019 May-Jun;26(4):740-747. doi: 10.1016/j.jmig.2018.08.008. Epub 2018 Aug 28.

MeSH Terms

Conditions

Pain, PostoperativeGenital Diseases, FemalePain

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNeurologic ManifestationsSigns and SymptomsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Hande Aytuluk, MD

    Derince Training and Research Hospital

    PRINCIPAL INVESTIGATOR
  • Ahmet Kale, Prof

    Derince Training and Research Hospital

    STUDY CHAIR
  • Gulfem Basol, MD

    Derince Training and Research Hospital

    STUDY CHAIR

Central Study Contacts

Hande Aytuluk, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D., Principal investigator

Study Record Dates

First Submitted

February 1, 2018

First Posted

February 9, 2018

Study Start

March 18, 2018

Primary Completion

June 30, 2018

Study Completion

July 1, 2018

Last Updated

March 20, 2018

Record last verified: 2018-03

Data Sharing

IPD Sharing
Will not share

The investigators do not prefer to share the study plan and records.

Locations